Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Dermatologic 2Other hematologic neoplasm 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Urinary Bladder Neoplasms 2Carcinoma, Transitional Cell 2Ureteral Neoplasms 1Recurrence 1Prostatic Neoplasms 1Neoplasm Metastasis 1Carcinoma 1

Interventions

Peripheral Blood Stem Cell Transplantation 6Cyclophosphamide 6fludarabine phosphate 5Nivolumab 5Mycophenolic Acid 5Carboplatin 5Whole-Body Irradiation 4Radiotherapy 4Filgrastim 4Cyclosporine 4Gemcitabine 3Cisplatin 3Busulfan 3Antilymphocyte Serum 3cabozantinib 2cabazitaxel 2Voriconazole 2Thiotepa 2Therapeutics 2Standard of Care 2Sirolimus 2Polymerase Chain Reaction 2Mitomycin 2Methylprednisolone 2Methotrexate 2Melphalan 2Itraconazole 2Immunoglobulin G 2Goserelin 2Flow Cytometry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Folic Acid × Genitourinary × Clear all
NCT00722553 2019-12-17

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Acrotech Biopharma Inc.

Phase 2 Completed
30 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡